BioStock: Aptahem’s new CMO on her role and vision

Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting another piece of the puzzle in place for future clinical studies with the drug candidate Apta-1, an emergency treatment for sepsis. BioStock contacted Hallberg to find out more about her background from the pharmaceutical industry and how she wants to guide Apta-1 through the next development steps.

Read the full interview with Ingela Hallberg at biostock.se:

https://www.biostock.se/en/2022/06/aptahems-new-cmo-on-her-role-and-vision/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/